OraSure Technologies, Inc. (NASDAQ:OSUR) Shares Purchased by Martingale Asset Management L P

Martingale Asset Management L P lifted its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 8.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 262,873 shares of the medical instruments supplier’s stock after buying an additional 19,926 shares during the quarter. Martingale Asset Management L P owned about 0.35% of OraSure Technologies worth $1,122,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of OSUR. BNP Paribas Financial Markets lifted its position in OraSure Technologies by 27.2% in the third quarter. BNP Paribas Financial Markets now owns 855,951 shares of the medical instruments supplier’s stock valued at $3,655,000 after acquiring an additional 183,191 shares during the last quarter. Intech Investment Management LLC purchased a new stake in shares of OraSure Technologies in the 3rd quarter valued at about $84,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of OraSure Technologies by 78.2% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 28,731 shares of the medical instruments supplier’s stock valued at $123,000 after purchasing an additional 12,604 shares during the last quarter. Factorial Partners LLC boosted its position in shares of OraSure Technologies by 12.0% in the 3rd quarter. Factorial Partners LLC now owns 339,953 shares of the medical instruments supplier’s stock valued at $1,452,000 after purchasing an additional 36,326 shares during the period. Finally, Empowered Funds LLC grew its stake in OraSure Technologies by 22.6% during the 3rd quarter. Empowered Funds LLC now owns 359,419 shares of the medical instruments supplier’s stock worth $1,535,000 after buying an additional 66,210 shares during the last quarter. Institutional investors and hedge funds own 93.50% of the company’s stock.

OraSure Technologies Trading Down 1.0 %

OraSure Technologies stock opened at $3.80 on Monday. The stock has a 50 day moving average of $4.09 and a two-hundred day moving average of $4.29. OraSure Technologies, Inc. has a twelve month low of $3.72 and a twelve month high of $8.45. The stock has a market capitalization of $283.46 million, a price-to-earnings ratio of 25.33 and a beta of 0.05.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.02. The firm had revenue of $39.92 million during the quarter, compared to the consensus estimate of $38.97 million. OraSure Technologies had a return on equity of 3.55% and a net margin of 5.07%. The company’s revenue for the quarter was down 55.2% on a year-over-year basis. During the same period last year, the company earned $0.27 earnings per share. Equities analysts predict that OraSure Technologies, Inc. will post -0.09 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on OSUR. StockNews.com raised OraSure Technologies from a “hold” rating to a “buy” rating in a report on Friday, October 4th. Evercore ISI raised their price objective on shares of OraSure Technologies from $4.50 to $5.00 and gave the stock an “in-line” rating in a research report on Wednesday, August 7th.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.